Abstract
Following austerity measures in Latvia, the reimbursement system faced major changes. Coagulation factor concentrates (CFC) used for hemophilia A treatment were moved to a reference list. This meant that government would only pay for the cheapest treatment included in the reimbursement system. Prescription rules did not change, but hematologists could no longer choose the treatment for their patients. Patients continued to attended their hemophilia center every three months, where they received special prescriptions for treatment according to their condition in line with Baltic Hemophilia treatment guidelines. During 2011–2016, 13 shortages were registered for CFCs for hemophilia A (2 products). Patients were not aware that the system must provide them with necessary treatment within 2 days from request in the drugstore. It was pharmacies’ responsibility to report shortages. Patients were instructed to report shortages to the Latvian Hemophilia Society, who, after verifying the fact with the respective pharmacy and wholesaler, reported the shortage to Health Inspection. Even when facts were confirmed by authorities, the reimbursement system did not react to shortages, and 11 times continued agreement with the distributor. In one case, the shortage was due to fact that the product was no longer produced, but no information was provided to the National Health Service of the Republic of Latvia (NHS). It took two months to exclude the product from the reimbursement system. In second case, the product was withdrawn from the system by the distributor, but immediately another product was provided for a similar price. The reimbursement system continued to function without patients’ involvement, with processes only between the paying authority, industry, wholesalers, pharmacies and doctors.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Behmane, D., & Innus, J. (2011). Pharmaceutical policy and the effects of the economic crisis: Latvia. Eurohealth, 17(1). Retrieved July 01, 2018, from http://apps.who.int/medicinedocs/documents/s20961en/s20961en.pdf.
Brooker, M. (2012). Registry of clotting factor concentrates (9th ed.). Montreal: World Federation of Hemophilia.
Cabinet of Ministers. (2017, October 23). Order No. 602. Par Plānu reto slimību jomā 2017–2020. gadam. Retrieved July 01, 2018, from https://likumi.lv/doc.php?id=294448.
Castaman, G., & Linari, S. (2018). Prophylactic versus on-demand treatments for hemophilia: Advantages and drawbacks. Expert Review of Hematology, 1–10. Retrieved July 01, 2018, from https://doi.org/10.1080/17474086.2018.1486704.
Central Bureau of Statistics. (2018). Population—Key indicators. Retrieved July 01, 2018, from http://www.csb.gov.lv/statistikas-temas/iedzivotaji-galvenie-raditaji-30260.html.
Clarke, G. (2011). Keeping the advocacy momentum going. Hemophilia World, December 2011. Retrieved July 01, 2018, from https://www.wfh.org/en/our-work/aia/advocacy-in-action-article-dec2011-en.
Council of Europe, Committee of Ministers. (2017, December 13). Resolution CM/Res(2017)43 on principles concerning haemophilia therapies (replacing Resolution CM/Res(2015)3). Retrieved July 01, 2018, from https://www.edqm.eu/sites/default/files/resolution_cm_res_2017_43_on_principles_concerning_haemophilia_therapies.pdf.
Franchini, M., & Mannucci, P. M. (2012). Past, present and future of hemophilia: A narrative review. Orphanet Journal of Rare Diseases, 7(24), 1–8. Retrieved July 01, 2018, from https://doi.org/10.1186/1750-1172-7-24.
Johnson, K. A., & Zhou, Z-Y. (2011). Costs of care in hemophilia and possible implications of health care reform. In ASH Education Book (Vol. 2011, no. 1, pp. 413–418). Retrieved July 01, 2018, from https://doi.org/10.1182/asheducation-2011.1.413.
LR Administratīvā apgabaltiesa. (2014, July 03). Case No. A420833010, Court Judgement AA43-1470-14/15. Retrieved July 01, 2018, from https://www.tiesas.lv/nolemumi/pdf/179022.pdf.
LR Cabinet of Ministers. (2006, October 31). Regulation No. 899: Procedures for the reimbursement of expenses toward the purchase of medicinal products and medical devices for the outpatient care. First published in Latvijas Vēstnesis, 180(3548). Retrieved July 01, 2018, from https://likumi.lv/doc.php?id=147522.
Ministry of Health. (2005). Official press release, January 25, 2005. Retrieved July 01, 2018, from http://www.vm.gov.lv/lv/aktualitates/preses_relizes/861_onkologisko_un_hematologisko_medikamentu_aprite_veiktas_izmainas/.
National Health Service. Diagnožu un vispārīgo nosaukumu saraksts. Retrieved July 01, 2018, from http://vmnvd.gov.lv/lv/kompensejamie-medikamenti/kompensejamo-zalu-saraksts.
National Health Service. Legislative acts database. Retrieved July 01, 2018, from http://ligumi.vmnvd.gov.lv/nas/library.nsf.
National Health Service. Operational statistics database. Retrieved July 01, 2018, from http://vmnvd.gov.lv/lv/503-ligumpartneriem/operativa-budzeta-informacija/valsts-budzeta-lidzeklu-izlietojums-valsts-kompensejamo-zalu-apmaksa. Analyzed by Latvia Hemophilia Society regularly since 2012 (Unpublished results).
Nacionālā veselības dienesta rīkojums Nr.16-2/137. (2018, June 21). Par izmaiņām Kompensējamo zāļu sarakstā. Latvijas Vēstnesis, June 22, 2018, Nr. 124 (6210). Retrieved July 01, 2018, from https://www.vestnesis.lv/op/2018/124.11.
O’Hara. (2017). The cost of severe haemophilia in Europe: The CHESS study. Orphanet Journal of Rare Diseases, 12, 106. Retrieved July 01, 2018, from https://doi.org/10.1186/s13023-017-0660-y.
Orphanet. (2009). Rare diseases: Hemophilia. Retrieved July 01, 2018, from https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=448.
Schrader, J., White, M., & Silberstein, P. (2007). Hemophilia. In xPharm: The comprehensive pharmacology reference. Elsevier. Retrieved July 01, 2018, from https://doi.org/10.1016/B978-008055232-3.63063-6.
Silins, J., & Szkultecka-Dębek, M. (2017). Drug policy in Latvia. Value in Health Regional Issues, 13, 73–78. Retrieved July 01, 2018, from https://doi.org/10.1016/j.vhri.2017.08.006.
Skinner, M. W. (2006). Treatment for all: A vision for the future. Haemophilia, 12(Suppl 3), 169–173. Retrieved July 01, 2018, from https://doi.org/10.1111/j.1365-2516.2006.01280.x.
Thomson, S., et al. (2014). Economic crisis, health systems and health in Europe: Impact and implications for policy. WHO Policy Summary 12. ISSN 2077-1584. Retrieved July 01, 2018, from http://apps.who.int/iris/bitstream/handle/10665/132050/Economic%20crisis,%20health%20systems?sequence=1.
World Federation of Hemophilia. (2012). Guidelines for the management of hemophilia (2nd ed.). Retrieved July 01, 2018, from https://www.wfh.org/en/resources/wfh-treatment-guidelines.
World Health Organization. (1977) Sections 10.2 and 11.2.2. In WHO model lists of essential medicines. Retrieved July 01, 2018, from http://www.who.int/medicines/publications/essentialmedicines/en/.
Acknowledgements
The author thanks COST ACTION CA15015 for focusing on medicines shortages situation and development of possible solutions.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ziemele, B. (2019). Patient Perspective: Reporting on Medicines Shortages—Hemophilia a Case in Latvia. In: Barbosa-Povoa, A., Jenzer, H., de Miranda, J. (eds) Pharmaceutical Supply Chains - Medicines Shortages. Lecture Notes in Logistics. Springer, Cham. https://doi.org/10.1007/978-3-030-15398-4_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-15398-4_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-15397-7
Online ISBN: 978-3-030-15398-4
eBook Packages: EngineeringEngineering (R0)